JP2022509017A5 - - Google Patents
Info
- Publication number
- JP2022509017A5 JP2022509017A5 JP2021523752A JP2021523752A JP2022509017A5 JP 2022509017 A5 JP2022509017 A5 JP 2022509017A5 JP 2021523752 A JP2021523752 A JP 2021523752A JP 2021523752 A JP2021523752 A JP 2021523752A JP 2022509017 A5 JP2022509017 A5 JP 2022509017A5
- Authority
- JP
- Japan
- Prior art keywords
- population
- cells
- cancer
- sequence
- genetically engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076832A JP2024097924A (ja) | 2018-11-07 | 2024-05-09 | 抗ｐｔｋ７免疫細胞癌療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756638P | 2018-11-07 | 2018-11-07 | |
| US62/756,638 | 2018-11-07 | ||
| US201962910586P | 2019-10-04 | 2019-10-04 | |
| US62/910,586 | 2019-10-04 | ||
| PCT/IB2019/059585 WO2020095248A1 (en) | 2018-11-07 | 2019-11-07 | Anti-ptk7 immune cell cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076832A Division JP2024097924A (ja) | 2018-11-07 | 2024-05-09 | 抗ｐｔｋ７免疫細胞癌療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509017A JP2022509017A (ja) | 2022-01-20 |
| JP2022509017A5 true JP2022509017A5 (enExample) | 2022-11-15 |
Family
ID=68582072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523752A Pending JP2022509017A (ja) | 2018-11-07 | 2019-11-07 | 抗ｐｔｋ７免疫細胞癌療法 |
| JP2024076832A Pending JP2024097924A (ja) | 2018-11-07 | 2024-05-09 | 抗ｐｔｋ７免疫細胞癌療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076832A Pending JP2024097924A (ja) | 2018-11-07 | 2024-05-09 | 抗ｐｔｋ７免疫細胞癌療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20210290678A1 (enExample) |
| EP (1) | EP3877421A1 (enExample) |
| JP (2) | JP2022509017A (enExample) |
| KR (1) | KR20210092236A (enExample) |
| CN (1) | CN112955472A (enExample) |
| AU (1) | AU2019374523A1 (enExample) |
| BR (1) | BR112021008083A2 (enExample) |
| CA (1) | CA3118830A1 (enExample) |
| CO (1) | CO2021005471A2 (enExample) |
| IL (1) | IL282532A (enExample) |
| MX (1) | MX2021005400A (enExample) |
| PH (1) | PH12021551047A1 (enExample) |
| SG (1) | SG11202104631SA (enExample) |
| WO (1) | WO2020095248A1 (enExample) |
| ZA (1) | ZA202102745B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115894696A (zh) * | 2021-08-18 | 2023-04-04 | 和迈生物科技有限公司 | 抗ptk7单域抗体及其应用 |
| WO2023084399A1 (en) * | 2021-11-09 | 2023-05-19 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7 |
| IL315366A (en) * | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| CN119403825A (zh) * | 2022-05-17 | 2025-02-07 | 阿森纳生物科学公司 | 靶向psma和ca9的工程化受体的系统 |
| US20260078201A1 (en) * | 2022-09-06 | 2026-03-19 | Uif (University Industry Foundation), Yonsei University | Anti-ptk7 antibody, and use thereof |
| EP4648854A1 (en) * | 2023-01-10 | 2025-11-19 | Expression Therapeutics, LLC | Engineered t cells |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| EP4684212A1 (en) * | 2023-03-22 | 2026-01-28 | Agilent Technologies, Inc. | Immunohistochemistry (ihc) ptk7 scoring protocols and methods for aiding cancer treatments |
| CN117085134A (zh) * | 2023-07-19 | 2023-11-21 | 浙江大学 | Ptk7抑制剂在制备预防或治疗肝癌的药物中的用途 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US12534529B1 (en) | 2024-11-19 | 2026-01-27 | Solve Therapeutics, Inc. | PTK7-binding proteins |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Ｃｎｎについての亜鉛フィンガー結合ドメイン |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| WO2015179801A1 (en) * | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
| TWI751102B (zh) * | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| KR102546839B1 (ko) * | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
| WO2019067805A1 (en) * | 2017-09-27 | 2019-04-04 | University Of Southern California | NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY |
| TW202208412A (zh) * | 2020-05-06 | 2022-03-01 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 對酪胺酸蛋白激酶樣７（ｐｔｋ７）特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞 |
-
2019
- 2019-11-07 CA CA3118830A patent/CA3118830A1/en active Pending
- 2019-11-07 JP JP2021523752A patent/JP2022509017A/ja active Pending
- 2019-11-07 US US17/291,194 patent/US20210290678A1/en not_active Abandoned
- 2019-11-07 KR KR1020217017025A patent/KR20210092236A/ko not_active Withdrawn
- 2019-11-07 US US16/677,207 patent/US12146157B2/en active Active
- 2019-11-07 EP EP19804869.6A patent/EP3877421A1/en active Pending
- 2019-11-07 SG SG11202104631SA patent/SG11202104631SA/en unknown
- 2019-11-07 WO PCT/IB2019/059585 patent/WO2020095248A1/en not_active Ceased
- 2019-11-07 BR BR112021008083-0A patent/BR112021008083A2/pt not_active Application Discontinuation
- 2019-11-07 MX MX2021005400A patent/MX2021005400A/es unknown
- 2019-11-07 AU AU2019374523A patent/AU2019374523A1/en not_active Withdrawn
- 2019-11-07 CN CN201980073056.0A patent/CN112955472A/zh active Pending
-
2021
- 2021-04-21 IL IL282532A patent/IL282532A/en unknown
- 2021-04-23 ZA ZA2021/02745A patent/ZA202102745B/en unknown
- 2021-04-27 CO CONC2021/0005471A patent/CO2021005471A2/es unknown
- 2021-05-06 PH PH12021551047A patent/PH12021551047A1/en unknown
-
2024
- 2024-05-09 JP JP2024076832A patent/JP2024097924A/ja active Pending
- 2024-11-14 US US18/947,327 patent/US20250074965A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022509017A5 (enExample) | ||
| JP2022513586A5 (enExample) | ||
| JP2024097924A5 (enExample) | ||
| JP2021522820A5 (enExample) | ||
| JP2022512882A5 (enExample) | ||
| IL278348B1 (en) | Methods and compositions for treating cancer | |
| CA2951355C (en) | Car-expressing nk-92 cells as cell therapeutic agents | |
| JP2020519641A5 (enExample) | ||
| US20250074965A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| JP2019531056A5 (enExample) | ||
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| HRP20171653T1 (hr) | Vezna sredstva koja služe ciljano protiv b7-h1 | |
| US20170159025A1 (en) | Nucleic acid for coding chimeric antigen receptor protein and t lymphocyte for expression of chimeric antigen receptor protein | |
| JP2020503870A5 (enExample) | ||
| JP2018529327A5 (enExample) | ||
| JP2019525771A5 (enExample) | ||
| JP2017506067A5 (enExample) | ||
| JP2018522072A5 (enExample) | ||
| JP2021511811A5 (enExample) | ||
| JP2017537620A5 (enExample) | ||
| JP2011157397A5 (enExample) | ||
| CA3118824A1 (en) | Anti-liv1 immune cell cancer therapy | |
| Gacerez et al. | Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression | |
| JP2021534784A5 (enExample) |